FC Lim
BioPharma IT Consulting Pte Ltd · Singapore
Over more than twenty years, FC Lim has worked across pharmaceutical and biotechnology digital investment — from greenfield biologics plant startup and regulatory approval, to multi-country ERP deployments, post-merger IT integration, MES implementation and stabilisation, and the emerging governance of autonomous systems in regulated manufacturing.
Twenty years. The same pattern in every engagement.
The FC Model™ emerged from direct experience across organisations of every size, in every region, at every level of digital maturity. The pattern it captures was not designed — it was observed, repeatedly, across pharmaceutical and biotechnology digital investments of every type.
Manufacturing Execution Systems (MES)
Greenfield deployments, forced migrations, multi-site rollouts, go-live stabilisation, and interface reliability between DCS, MES, and ERP layers. Regulatory defensibility at every level of complexity.
Computer Systems Validation (CSV)
Validated states that survive regulatory inspection — across FDA 21 CFR Part 11, EU Annex 11, HSA, MHRA, and TGA jurisdictions. Data integrity governance from design through decommission.
ERP and Data Integration
Multi-country ERP deployments, Finance Shared Services consolidation, CMO data connectivity, and data standards decisions that determine whether Level 2 is possible at all. The decisions that are expensive to reverse.
Digital Investment Strategy
The FC Model™ diagnostic applied before investment approval — identifying the level of maturity the organisation is actually targeting, and whether the scope is designed to reach it. The conversation that usually does not happen.
Regulatory Inspection Preparation
Regulatory inspection preparation and real-time support across FDA, EMA, HSA, MHRA, and TGA environments. Batch record traceability, deviation management, and the validated state that holds under scrutiny.
Autonomous Systems Governance
Advisory on the accountability and governance questions that autonomous systems in regulated environments force upon the industry — including the first dedicated EU GMP Annex 22 framework for AI, published for consultation in July 2025 and not yet finalised.
The organisations that shaped the pattern.
FC Lim's career spans roles at organisations ranging from startup biotechnology sites to some of the world's largest pharmaceutical companies — in project management, IT leadership, digital investment strategy, and independent advisory.
Prior organisation names included here as part of FC Lim's career biography. The current engagement is described by role rather than by name. Cases in the book are separately anonymised — no employer is identified in the case studies.
Five regulatory environments. One consistent standard.
FDA — 21 CFR Part 11
Electronic records and signatures in US-regulated pharmaceutical and biotechnology manufacturing.
EMA — EU Annex 11
Computerised systems in GMP-regulated European pharmaceutical manufacturing, including the new EU GMP Annex 22 for AI (published for consultation July 2025, not yet finalised).
HSA — Health Sciences Authority
Singapore regulatory authority for health products and GMP-regulated pharmaceutical manufacturing.
TGA — Therapeutic Goods Administration
Australian regulatory authority for therapeutic goods including prescription medicines and biologics.
MHRA — Medicines and Healthcare products Regulatory Agency
UK regulatory authority for medicines and medical devices, including GMP inspection.
What distinguishes principal advisory from implementation consulting.
Every organisation I work with has technically capable people. What distinguishes principal advisory is not technical knowledge. It is the cross-case pattern — having seen this scenario in multiple variations across different organisations and regulatory environments — and the organisational standing to name what the internal team already suspects but cannot say in the approval room.
Cross-case pattern recognition
Seven real cases in one book. Dozens more in two decades of practice. The pattern that emerges is structural — it repeats across organisations of every size, in every region. Seeing it clearly is the first step to asking the right question before the next investment.
Organisational independence
An internal team carries two constraints an external advisor does not: altitude (the people who understand the technical landscape are rarely the same people who can challenge the investment case at CFO or site head level) and social standing (pointing out that the approved scope is insufficient, before the project has started, requires an independence that is difficult to sustain from inside).
The Drucker principle
The right question, at the right moment, asked by the right person. Peter Drucker observed that management is doing things right; leadership is doing the right things. Digital investment strategy is about ensuring the organisation is asking the right question before approving the wrong scope — and knowing which question to ask at which moment.
"What distinguishes principal advisory from implementation consulting is not primarily technical knowledge. It is the cross-case pattern — having seen this scenario in multiple variations — and the organisational social standing to name what the internal team already suspects but cannot say in the approval room."— FC Lim, Before the Next Digital Investment
Every engagement is principal-led. No delegation to associates.
BioPharma Advisory is a principal practice. That means FC Lim is the advisor in every engagement — not a relationship manager who delegates to a junior team. The value of the practice is the cross-case pattern that two decades of direct experience has built. That cannot be delegated.
The practice works with a small number of clients at any time, to ensure that the engagement quality every client receives is what the practice was built to deliver.